Date of Document: March 29, 2024

CURRICULUM VITAE

Qizhen Shi MD, PhD

Professor
Department of Pediatrics
Division of Hematology and Oncology - Pediatrics
Senior Investigator
Blood Research Institute
BloodCenter of Wisconsin

OFFICE ADDRESS:
The Blood Research Institute
8727 Watertown Plank Rd
Milwaukee, WI 53226

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Shi Q, Lu L, Zhang X. Genetic diagnosis of hemophilia A using Polymerase Chain Reaction. Transfusion and Hematology 1994, 17 (4): 202-205.
2. Shi Q, Lu L, Zhang X. A rapid method of DNA template preparation for PCR without DNA extraction. Journal of Fujian Medical University 1994, 28 (4): 418-420.
3. Liu J, Chen H, Zhang J, Erica V, Yi H, Zheng S, Shi Q, Wang H, Sommer SS. Study of gene mutation of FIX B patients from China. High Technology Letters 1994, 8:29-32.
4. Shi Q, Lu L, Zhang X. Genetic diagnosis of hemophilic carriers by PCR/RFLP. Chinese Journal of Medical Genetics 1995, 12 (2): 107-108.
5. Shi Q, Lu L, Zhang X. Study of polymorphism in the factor VIII gene by polymerase chain reaction. Chinese Journal of Experimental Hematology 1995, 3 (3): 303-307.
6. Liu J, Xiang H, Liu L, Zhou H, Zhang J, Shi Q, Chen H, Zhen S, Sommer SS. Diagnosis using Genomic Amplification with Transcripts Sequencing (GAWTS). Chinese Journal of Medicine 1995, 75 (10): 599-601.
7. Shi Q, Lu L, Xing B, Guo R. Detection of cytomegalovirus infection in leukemia by polymerase chain reaction. Chinese Journal of Hematology 1996, 17 (1): 38.
8. Shi Q, Lu L, Chen Z, Huang S. Chronic myelogenous leukemia complicated with malignant lymphoma. Chinese Journal of Clinical Oncology and Rehabilitation 1996, 3 (4): 56-59.
9. Shi Q, Lu L. Gene therapy of chronic myelogenous leukemia by use of antisense technology. Journal of Fujian Medical University 1997, 31 (4): 458-460.
10. Shi Q, Lu L, Zhang X. Study of Bcl I and Hind III polymorphisms in the factor VIII gene by PCR. Chinese Journal of Birth Health and Heredity 1997, 5 (6): 21-23.
11. Shi Q, Lu L. The efficacy of c-myb antisense phosphorothioate oligonucleotides on K562 cells. Chinese Journal of Hematology 1999, 20 (7): 371-372.
12. Shi Q, Lu L, Hu J, Yang Y, Chen Y. The effect of antisense bcr-abl oligonucleotides on the cell growth of K562 cells. Chinese Journal of Pathophysiology 2000, 16 (4): 342-346.
13. Shi Q, Lu L. The effect on K562 cells by combining bcr/abl and c-myb antisense oligonucleotides. Chinese Journal of Oncology Biotherapy 2000, 7 (4): 251-254.
14. Shi Q, Lu L, Zhan R, Hu J. The expression of Wt1 gene in hematopoietic malignant disease and its relation to prognosis. Chinese Journal of Medical Genetics 2000, 17 (4): 301-302.
15. Shi Q, Huang H, Chen Z, Lu L. The efficacy of alky-lysophospholipid ET-18- OCH3 on K562 cells. Journal of Cell Biology 2001, 23 (2): 98-102.
16. Shi Q, Lu L, Chen Y, Hu J. Gene expression inhibitory and apoptosis of K562 cells by bcr/abl antisense oligonucleotides. Chinese Journal of Applied Physiology 2001, 17 (3): 213-216.

17. Chen Y, Yang Y, Lu L, Shi Q. Detection and Analysis of P16 Gene Deletion in Acute Lymphocytic Leukemia. Chinese New Medicine, 2002; 3(5): 405-406.
18. Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR. Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. Mol Genet Metab. 2003 May;79(1):25-33.
19. Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood. 2003 Dec 01;102(12):4006-13.
20. Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost. 2003 Dec;1(12):2477-89.
21. Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, Montgomery RR. Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. J Thromb Haemost. 2004 Nov;2(11):1989-97.
22. Chen Y, Shi Q, Lu L, Hu J. The inhibition of bcr/abl antisense on chronic myelocyte leukemia (CML) primary cells. Chinese Journal of Pathology. 2005; 21(2):400-402.
23. Haberichter SL, Shi Q, Montgomery RR. The biology of von Willebrand factor and factor VIII-regulated release. Hematologica Reports 2005, 1 (6): 9-14.
24. Haberichter SL, Shi Q, Montgomery RR. Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer. 2006 May 01;46(5):547-53.
25. Shi Q, Wilcox DA, Fahs SA, Weiler H, Well CC, Cooley BC, Desai D, Morateck PA, Gorski J, and Montgomery RR Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 2006, 116 (7):1974-1982. PMCID: PMC1483176. Featured article: “In This Issue”. High, K.A. The leak stops here: platelets as delivery vehicles for coagulation factors. J Clin Invest 2006, 116 (7): 1840-1842.
26. Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost. 2007 Feb;5(2):352-61.
27. Shi Q,* Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, Weiler H, and Montgomery RR. Syngeneic transplantation of hematopoietic stem cells (HSC) that are genetically modified to express factor VIII (FVIII) in platelets restores hemostasis to hemophilia A mice with pre-existing FVIII immunity. Blood 2008,112 (7):2713-2721. Featured article: “In This Issue”. Tuddenham E. G. D. Killing 2 birds with 1 stone. Blood 2008,112 (7):2595. *Corresponding author. PMCID: PMC2556608.
28. Zhang G, Shi Q, Fahs SA, Kuether EL, Walsh CE, Montgomery RR. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice. Blood. 2010 Aug 26;116(8):1235-43. PMCID: PMC2938234
29. Shi Q, Fahs SA, Kuether EL, Cooley BC, Weiler H, Montgomery RR. Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. Blood. 2010 Oct 21;116(16):3049-57. PMCID: PMC2974610
30. Shi Q, Montgomery RR. Platelets as delivery systems for disease treatments. Adv Drug Deliv Rev. 2010 Sep 30;62(12):1196-203. PMCID: PMC2991519
31. Montgomery RR, Shi Q. Alternative strategies for gene therapy of hemophilia. Hematology Am Soc Hematol Educ Program. 2010;2010:197-202. PMCID: PMC3383974.
32. Kanaji S, Kuether EL, Fahs SA, Schroeder JA, Ware J, Montgomery RR, Shi Q. Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy. Mol Ther. 2012 Mar;20(3):625-32. PMCID: PMC3293608
33. Montgomery RR, Shi Q. Platelet and endothelial expression of clotting factors for the treatment of hemophilia. Thromb Res. 2012 May;129 Suppl 2(Suppl 2):S46-8. PMCID: PMC3581347
34. Shi Q, Kuether EL, Schroeder JA, Fahs SA, Montgomery RR. Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice. Haemophilia. 2012 Jul;18(4):639-46. PMCID: PMC3323668
35. Kuether EL, Fahs SA, Cooley BC, Schroeder JA, Chen Y, Montgomery RR, Wilcox DA, and Shi Q*. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-FVIII immunity. J Thromb Haemost. 2012 Aug;10(8):1570-80. Featured article: “In This Issue”. Chuah, M. and Vanderdriessche, T. Platelet-directed gene therapy overcomes inhibitory antibodies to FVIII. J Thromb Haemost 2012; 10(8): 1566-1569]. *Corresponding author. PMCID: PMC3419807.

36. Shi Q, Kuether EL, Schroeder JA, Perry CL, Fahs SA, Cox Gill J, Montgomery RR. Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo. J Thromb Haemost. 2012 Nov;10(11):2328-37. PMCID: PMC3670966
37. Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost. 2012 Aug;10(8):1646-52. PMCID: PMC3419786
38. Du LM, Nurden P, nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Paymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, and Wilcox, D.A. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun. 2013 Nov 19;4:2773:1-11. doi: 10.1038/ncomms3773. Featured article: “Cover of Nature Home”. PMCID: PMC3868233
39. Chen Y, Schroeder JA, Kuether EL, Zhang G, Shi Q. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice. Mol Ther. 2014 Jan;22(1):169-77. PMCID: PMC3978792
40. Shi Q,* Kuether EL, Chen Y, Schroeder JA, Fahs SA, and Montgomery RR. Platelet gene therapy corrects the hemophilic phenotype in immunocompromized hemophilia A mice transplanted with genetically manipulated human cord blood stem cells. Blood 2014, 123(3):395-403. * Corresponding author. PMCID: PMC3894495.
41. Fahs SA, Hille MT, Shi Q, Weiler H, and Montgomery RR. Conditional knockout mouse model reveals endothelial cells as the predominant and possibly exclusive source of plasma factor VIII. Blood 2014 Jun 12, 123(24):3706-13. Featured article: “In This Issue”. Ed Tuddenham. In search of the source of factor VIII. Blood, 2014;123(24):3691. Article also got highlighted as being among the “hottest” new studies by the editors. PMCID: PMC4055921.
42. Schroeder JA, Chen Y, Fang J, Wilcox DA, and Shi Q*. In vivo enrichment of manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infectious. J Thromb Haemost. 2014 Aug; 12(8):1283-93. * Corresponding author. PMCID: PMC4127102.
43. Kanaji S, Fahs SA, Ware J, Montgomery RR, and Shi Q. Non-myeloablative conditioning with busulfan prior to hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard Soulier Syndrome. J Thromb Haemost. 2014 Oct; 12(10):1726-32. PMCID: PMC4194147.
44. Mannucci PM, Shi Q, Bonanad S, Klamroth R. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development. Haemophilia. 2014 Sep;20 Suppl 6:2-16.
45. Shi Q,* Schroeder JA, Kuether EL, and Montgomery RR. The important role of von Willebrand factor in platelet-derived factor VIII gene therapy of murine hemophilia A in the presence of inhibitory antibodies. J Thromb Haemost. 2015 July; 13(7): 1301–1309. * Corresponding author. PMCID: PMC 4496307.
46. Baumgartner KC, Kuether EL, Zhang G, Weiler H, Shi Q,* and Montgomery RR. Native whole blood thrombin generation assay evaluates therapeutic efficacy of plasma and platelet-derived FVIII. J Thromb Haemost. 2015 Dec; 13(12):2210-2219. * Corresponding author. PMCID:PMC4715732.
47. Chen Y, Schroeder JA, Chen J, Luo X, Baumgartner KC, Montgomery RR, Hu J, and Shi Q.* The immunogenicity of platelets containing FVIII in murine hemophilia A with or without pre-existing anti-FVIII immunity. Blood 2016 Mar 10, 127(10): 1346-54. Featured article: “In This Issue”. Ragni, M.V. Platelet VIII pack evades immune detection. Blood 2016, 127(10): 1222-24. Article also got highlighted as being among the “hottest” new studies by Editor-in-Chief. * Corresponding author. PMCID: PMC4786841.
48. Haribhai D, Luo X, Chen J, Jia S, Shi L, Schroeder JA, Hessner MJ, Aster D, Hu J,* Williams CB,* and Shi Q* TGF-?1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice. Blood Advances 2016 Dec 13, 1(2): 139-151. Featured article. Article was highlighted in “Advance Notice” Newsletter by Editor-In-Chief. *Corresponding author. PMID 28164173. PMCID: PMC5288643.
49. Baumgartner KC, Mattson JG, Weiler H, Shi Q,* and Montgomery RR. Targeting FVIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice. J Thromb Haemost. 2017 Jan;15(1):98-109. PMCID: PMC5280575. *Corresponding author. Featured article: “In This Issue”. Tuddenham E. G. D. Platelets are a safe way to deliver factor VIII. After 13 years of preclinical research it is now time for a clinical trial.
50. Chen Y, Luo X, Schroeder JA, Chen J, Baumgartner CK, Hu J, Shi Q. Immune tolerance induced by platelet-targeted Factor VIII gene therapy in hemophilia A mice is CD4 T cell-mediated. J Thromb Haemost.

2017 Oct;15(10):1994-2004. PMID: 28799202. PMCID: PMC5630523.
51. Chen J, Schroeder JA, Luo X, Shi Q*. The impact of von Willebrand factor on factor VIII memory immune responses. Blood Adv. 2017 Aug 22;1(19):1565-1574. Featured article. Article was highlighted in "Advance Notice" Newsletter by Editor-In-Chief. *Corresponding author. PMCID: PMC5600162
52. Shi Q. Platelet-Targeted Gene Therapy for Hemophilia. Mol Ther Methods Clin Dev. 2018 Jun 15;9:100-108. PMCID: PMC5842292
53. Luo X, Chen J, Schroeder JA, Allen KP, Baumgartner CK, Malarkannan S, Hu J, Williams CB, Shi Q. Platelet Gene Therapy Promotes Targeted Peripheral Tolerance by Clonal Deletion and Induction of Antigen-Specific Regulatory T Cells. Front Immunol. 2018;9:1950. PMCID: PMC6136275
54. Chen J, Schroeder JA, Luo X, Montgomery RR, Shi Q. The impact of GPIb? on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity. J Thromb Haemost. 2019 Mar;17(3):449-459. PMCID: PMC6397061
55. Wang D, Zhang G, Gu J, Shao X, Dai Y, Li J, Pan X, Yao S, Xu A, Jin Y, Huang J, Shi Q, Zhu J, Xi X, Chen Z, Chen S. In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A. Haematologica. 2020 Apr;105(4):e175-e179. PMCID: PMC7109733
56. Gao C, Schroeder JA, Xue F, Jing W, Cai Y, Scheck A, Subramaniam S, Rao S, Weiler H, Czechowicz A, Shi Q. Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice. Blood Adv. 2019 Sep 24;3(18):2700-2711. PMCID: PMC6759737
57. Jing W, Chen J, Cai Y, Chen Y, Schroeder JA, Johnson BD, Cui W, Shi Q. Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice. Blood Adv. 2019 Oct 22;3(20):3099-3110. PMCID: PMC6849959
58. Shi Q, Mattson JG, Fahs SA, Geurts AM, Weiler H, Montgomery RR. The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression. Blood Adv. 2020 Jan 14;4(1):55-65. PMCID: PMC6960468
59. Garcia J, Flood VH, Haberichter SL, Fahs SA, Mattson JG, Geurts AM, Zogg M, Weiler H, Shi Q, Montgomery RR. A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9. Res Pract Thromb Haemost. 2020 Jan;4(1):64-71. PMCID: PMC6971331
60. Shi Q, Carman CV, Chen Y, Sage PT, Xue F, Liang XM, Gilbert GE. Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice. Blood Adv. 2020 May 26;4(10):2272-2285. PMCID: PMC7252558
61. Chen Y, Schroeder JA, Gao C, Li J, Hu J, Shi Q. In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy. J Cell Physiol. 2021 Jan;236(1):354-365. PMCID: PMC7722216
62. Cai Y, Shi Q. Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A. Front Immunol. 2020;11:964. PMCID: PMC7303294
63. Li J, Chen J, Schroeder JA, Hu J, Williams CB, Shi Q. Platelet gene therapy induces robust immune tolerance even in a primed model via peripheral clonal deletion of antigen-specific T cells Molecular Therapy - Nucleic Acids. 5 March 2021;23:719-730.
64. Li J, Chen J, Schroeder JA, Hu J, Williams CB, Shi Q. Platelet gene therapy induces robust immune tolerance even in a primed model via peripheral clonal deletion of antigen-specific T cells. Mol Ther Nucleic Acids. 2021 Mar 05;23:719-730. PMCID: PMC7851450
65. Schroeder JA, Chen J, Chen Y, Cai Y, Yu H, Mattson JG, Monahan PE, Shi Q. Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity. Blood Adv. 2021 Mar 09;5(5):1224-1238. PMCID: PMC7948262
66. Schroeder JA, Kuether EA, Fang J, Jing W, Weiler H, Wilcox DA, Montgomery RR, Shi Q. Thromboelastometry assessment of hemostatic properties in various murine models with coagulopathy and the effect of factor VIII therapeutics. J Thromb Haemost. 2021 Oct;19(10):2417-2427. PMCID: PMC8865566
67. Shi Q, Fahs SA, Mattson JG, Yu H, Perry CL, Morateck PA, Schroeder JA, Rapten J, Weiler H, Montgomery RR. A novel mouse model of type 2N VWD was developed by CRISPR/Cas9 gene editing and recapitulates human type 2N VWD. Blood Adv. 2022 May 10;6(9):2778-2790. PMCID: PMC9092403
68. Chen Y, Luo L, Zheng Y, Zheng Q, Zhang N, Gan D, Yirga SK, Lin Z, Shi Q, Fu L, Hu J, Chen Y. Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia. Front Immunol. 2022;13:810620. PMCID: PMC9016750
69. Shi Q, Weiler H. Blocking hemophilic arthropathy. Blood. 2022 May 05;139(18):2734-2735.
70. Cai Y, Schroeder JA, Jing W, Gurski C, Williams CB, Wang S, Dittel BN, Shi Q. Targeting transmembrane-

domain-less MOG expression to platelets prevents disease development in experimental autoimmune encephalomyelitis. Front Immunol. 2022;13:1029356. PMCID: PMC9647046

71. Luo L, Zheng Q, Chen Z, Huang M, Fu L, Hu J, Shi Q, Chen Y. Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications. Front Immunol. 2022;13:1019275. PMCID: PMC9774473
72. Jing W, Baumgartner CK, Xue F, Schroeder JA, Shi Q. Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells. J Thromb Haemost. 2023 Mar;21(3):488-498.
73. Kumar S, Schroeder JA, Shi Q. Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond. J Thromb Haemost. 2024 Jan;22(1):23-34.
74. Biswas R, Boyd EK, Eaton N, Steenackers A, Schulte ML, Reusswig F, Yu H, Drew C, Kahr WHA, Shi Q, Plomann M, Hoffmeister KM, Falet H. PACSIN2 regulates platelet integrin ?1 hemostatic function. J Thromb Haemost. 2023 Dec;21(12):3619-3632. PMCID: PMC10841284
75. Li J, Karakas D, Xue F, Chen Y, Zhu G, Yucel YH, MacParland SA, Zhang H, Semple JW, Freedman J, Shi Q, Ni H. Desialylated Platelet Clearance in the Liver is a Novel Mechanism of Systemic Immunosuppression. Research (Wash D C). 2023;6:0236. PMCID: PMC10551749
76. Strilchuk AW, Hur WS, Batty P, Sang Y, Abrahams SR, Yong ASM, Leung J, Silva LM, Schroeder JA, Nesbitt K, de Laat B, Moutsopoulos NM, Bugge TH, Shi Q, Cullis PR, Merricks EP, Wolberg AS, Flick MJ, Lillicrap D, Nichols TC, Kastrup CJ. Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A. Sci Transl Med. 2024 Feb 21;16(735):eadh0027.

Books, Chapters, and Reviews

1. Shi Q, Zhang X. Genetic Diagnosis of hemophilia A using PCR/RFLP. Diagnosis and Treatment of Blood Disorders, Fujian Union Hospital 2005, p.336-343
2. Shi, Q. and Montgomery R. Platelet Gene Therapy. Platelets in Thrombotic and Non-thrombotic Disorders - Pathophysiology, Pharmacology and Therapeutics. Springer, SPi, 2017. Pp1430-1444. *Corresponding author.
3. Shi Q, Montgomery RR. Gene therapy Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: an Update. 8 March 2017:1431-1445.

Abstracts

1. Shi Q, Lu L, and Zhang X. Diagnosis of hemophilia A carriers using PCR/RFLP strategy. The 4th Chinese National Experimental Hematology Meeting, Guangzhou, Guangdong, China. November, 1993. Accepted for oral presentation.
2. Shi Q, and Lu L. Study the effect of c-myb antisense oligonucleotides on K562 cells. The 3rd Fujian Science-technology Youth Academic Conference, Fuzhou, Fujian, China. July, 1998. Accepted for oral presentation.
3. Shi Q, Lu L, Hu J, Yang Y, and Chen Y. Study the effect of bcr/abl antisense oligonucleotides on K562 cells. The 1st Min-Tai Medical Association Congress and the 8th Fujian Provincial Hematology Meeting. Wuyishan, Fujian, China. November, 1998. Accepted for oral presentation.
4. Shi Q, Lu L, Chen Y, Zhan R, and Hu J. The inhibition of bcr/abl antisense on chronic myelocyte leukemia (CML) primary cells. The 10th Chinese National Experimental Hematology Meeting. Kunming, Yunnan, China. November, 1999. Accepted for Oral presentation.
5. Shi Q, Zhi Z, and Lu L. The effect of alky-lysophospholipid ET-18-OCH3 on K562 cells. The 8th Chinese Hua-Dong (East China) Hematology Conference. Xiamen, Fujian, China. May 22-25, 2000. Accepted for Oral presentation.
6. Shi Q, and Lu L, Zhan R, Hu J. The expression of wt1 gene in hematopoietic malignant disease and its relation to prognosis. The 8th Chinese Hua-Dong (East China) Hematology Conference. Xiamen, Fujian, China. May 22-25, 2000.
7. Montgomery RR, Haberichter S, Shi Q, Gavazova S, Kroner PA. The Trafficking of the VWF Propeptide (VWFpp) and its Effect On Co-Trafficking of von Willebrand Factor (VWF) and Factor VIII (FVIII). 18th International Congress of Clinical Chemistry and Laboratory Medicine (Symposium), 2002.
8. Shi Q, Fahs SA, Wilcox DA, Kroner PA, and Montgomery RR. Endothelial, platelet, and liver-specific expression of FVIII and the effect of VWF storage. Blood 2002; 102: 490a.
9. Shi Q, Fahs SA, Wilcox DA, Kroner PA, Montgomery RR. Endothelial platelet liver-specific expression of FVIII the effect of VWF storage. Blood (ASH Annual Meeting Abstracts) 2002;102:490a.

10. Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, and Montgomery RR. Tissue-specific expression of GPIb? in human megakaryocytes. The 27th Annual Children Hospital of Wisconsin Residents and Fellows Research Days, Milwaukee, WI, 2003.
11. Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, Montgomery RR. Targeting GPIb? transgene expression to human megakaryocytes using lentivirus vector its possible for gene therapy of Bernard-Soulier Syndrome. Blood (ASH Annual Meeting Abstracts) 2003;102:288a-289a.
12. Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White II GC, Montgomery RR. EM localization agonist-induced release of human factor VIII from megakaryocytes transduced with a FVIII transgene. Blood (ASH Annual Meeting Abstracts) 2003;102:87a.
13. Yarovoi HE, King MS, Eslin DE, Haberichter SL, Shi Q, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, and Poncz M. Demonstration that platelet-expressed human B-Domainless factor VIII can ameliorate the bleeding diathesis in a murine model of hemophilia A. Blood 2003; 102: 53a.
14. Montgomery RR, Haberichter SL, Shi Q, Kroner PA, Gill JC, Wilcox DA, and Nichols TC. Molecular synthesis and trafficking of VWF. The 44th Annual Meeting of American Society of Hematology, San Diego, California, CA, Dec. 6-9, 2003.
15. Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, Weiler H, and Montgomery RR. Sustained phenotypic correction of murine hemophilia A by platelet-specific gene therapy. Midwest Platelet Conference, Milwaukee, 2004.
16. Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, Weiler H, Montgomery RR. Lentivirus-Mediated Platelet-Specific Gene Therapy of Hemophilia A. Blood (ASH Annual Meeting Abstracts), Nov 2004; 104: 2974.
17. Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, Weiler H, Montgomery RR. Murine hemophilia A is phenotypically corrected by platelet-expressed factor VIII even in the absence of detectable plasma FVIII. J Thromb Haemost 2005;3 Supplement 1:OR186.
18. Shi Q, Wilcox DA, Fahs SA, Weiler H, Montgomery RR. Platelet-derived factor VIII (FVIII) is protected from inhibitor inactivation – A potential approach for gene therapy of hemophilia A with inhibitors. J Thromb Haemost 2005;3 Supplement 1:H05.
19. Shi Q., Weiler H., Haberichter S.L., Cooley B.C., Fahs S.A., Desai D., Wandersee N.J., Jozwiak M.A., and Montgomery R.R. Transgenic Targeting of Human FVIII Expression to Endothelial Cells Corrects the Murine Hemophilia A Phenotype and Re-Establishes a Releasable Pool of FVIII Together with VWF. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 3056.
20. Shi Q, Weiler H, Haberichter SL, Cooley BC, Fahs SA, Desai D, Wandersee NJ, Jozwiak MA, and Montgomery RR: Transgenic Targeting of Human FVII Expression to Endothelial Cells Corrects the Murine Hemophilia A Phenotype and Re-establishes a Releasable pool of FVIII Together with VWF. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 3056.
21. Shi Q, Wilcox DA, Fahs SA, Cooley BC, Desai D, Weiler H, Morateck PA, Montgomery RR. Platelet-Derived Factor VIII (FVIII) Corrects the Murine Hemophilia A Phenotype Even in the Presence of FVIII Inhibitors. Blood (ASH Annual Meeting Abstracts), Nov 2005;106:457.
22. Shi Q, Fahs SA, Wilcox DA, Weiler H, Haberichter SL, Montgomery RR: Targeting FVIII Expression to Platelets and endothelial Cells Resulting in Divergent Clinical Effect in Murine Hemophilia A With and without FVIII Inhibitory Antibodies. Midwest Platelet Conference, Chicago, 2006.
23. Montgomery RR, and Shi Q. Ectopic expression of FVIII in platelets corrects the murine hemophilia A phenotype even in the presence of high-titer FVIII inhibitors. The 8th Workshop on Novel Technologies and Gene Transfer for Hemophilia at The Children's Hospital of Philadelphia. 2006.
24. Wilcox DA, Shi Q, Poncz M, and Montgomery RR. Targeting coagulation factor VIII to platelet for gene therapy of hemophilia A. The Australian Society of Thrombosis and Haemostasis Meeting. Australia, 2006
25. Shi Q, Wilcox DA, Fahs SA, and Montgomery RR. Ectopic expression of FVIII in platelets as a model approach to gene therapy of hemophilia A patients with inhibitors. Pediatrics Academic Society Annual Meeting, San Francisco, 2006.
26. Shi Q, Fahs SA, Wilcox DA, Weiler H, Haberichter SL, Montgomery RR. Endothelial and Platelet FVIII/VWF Expression - Divergence in Clinical Effect in Murine Models of Hemophilia A with and without FVIII Inhibitory Antibodies. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 3286.
27. Shi Q, Fahs SA, Wilcox DA, Weiler H, Montgomery RR. Transplant bone marrow that is genetically modified to express FVIII only in platelets can restore hemostasis to hemophilia A mice on a strong inhibitor background. J Thromb Haemost 2007;5 supplement 2:P-W-232
28. Shi Q, Fahs SA, Kuether EL, Montgomery RR. The Effect of von Willebrand Factor (VWF) on Site-Specific

Factor VIII (FVIII) Expression in Hemophilia A Mice. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 764.
29. Shi Q, Fahs SA, Wilcox DA, Kuether EL, Weiler H, Montgomery RR. In the presence of pre-existing factor VIII (FVIII) immunity hematopoietic stem cells (HSC) that are genetically modified to express FVIII in platelets were successfully transplanted into hemophilic mice under myeloablative various non-myeloablative conditions. Blood (ASH Annual Meeting Abstracts) 2007;110:235a
30. Zhang G, Shi Q, Fahs SA, Walsh CE, Montgomery RR. Ectopic Expression of Human FIX in Mouse Platelets Can Store Releasable FIX in Platelets and May Be a Potential Strategy for Gene Therapy of Hemophilia B. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 196.
31. Shi Q, Fahs SA, Wilcox DA, Montgomery RR. Syngeneic transplantation of hematopoietic progenitor cells that are genetically modified to express FVIII in platelets can efficiently restore hemostasis to hemophilia A mice with pre-existing FVIII inhibitory antibodies. Haemophilia 2008
32. Shi Q. Platelet and endothelial FVIII/VWF expression in hemophilia gene therapy. The 9th Workshop on Novel Technologies and Gene transfer for Hemophilia, The Children's Hospital of Philadelphia. February, 2008.
33. Montgomery RR, Shi Q, Zhang G. Factor VIII and beyond – the platelet for targeted drug delivery in hemophilia. The 6th Bari International Conference, Italy, May 2008.
34. Shi Q. Platelet-specific Gene therapy of hemophilia A and hemophilia A with inhibitors. The Physician/Researcher track of NHF's 60th Annual Meeting, Denver, CO, November 2008.
35. Wilcox DA, Du LM, Haberichter SL, Jacobi PM, Fang J, Jensen ES, Shi Q, Montgomery RR. Platelet-Targeted Expression of Coagulation Factor VIII (FVIII) Shows Efficacy for Using the Dog as a Large Animal Model for Gene Therapy of Hemophilia A. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3525.
36. Zhang G, Montgomery RR, Fahs SA, and Shi Q. Gene Therapy of Hemophilia B Using Platelet-specific Expression of Factor IX (FIX). The 2009 Pediatric Academic Societies' Annual Meeting, Baltimer, ML, May 2009.
37. Montgomery RR, Haberichter SL, Jozwiak M, Fahs SA, and Shi Q. Factor VIII and von Willebrand Factor – the confusion of the 70's persists to today. J Thromb Haemost 2009, 7 supplement 2: 975-976. PP-TH-128.
38. Du LM, Nichols TM, Haberichter SL, Jacobi PM, Jensen ES, Fang J, Shi Q, Montgomery RR, Wilcox DA. Platelet-Targeted Expression of Human BDD-FVIII Reduces Bleeding in Canine Hemophilia A. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 691.
39. Shi Q, Kuether EL, Zhang G, Schroeder JA, Fahs SA, Montgomery RR. Intraperitoneal Injection and Recovery of VWF and FVIII and Differences From Intravenous and Subcutaneous Injection. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 3178.
40. Shi Q, Kuether EL, Cooley BC, Fahs SA, Schroeder JA, Wilcox DA, Montgomery RR. Sustained Phenotypic Correction of Murine Hemophilia A with Pre-Existing Anti-FVIII Immunity Using Lentivirus-Mediated Platelet-Specific FVIII Gene Transfer. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 29.
41. Shi Q, Kuether EL, Schroeder JA, Perry CL, Fahs SA, Montgomery RR. Factor VIII Inhibitors: Von Willebrand Factor Makes A Difference In Vitro and In Vivo. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 709.
42. Shi Q, Kuether EL, Schroeder JA, Fahs SA, Wilcox DA, Montgomery RR. The Important Role of Von Willebrand Factor In Platelet-Derived FVIII Gene Therapy of Murine Hemophilia A In the Presence of Inhibitors Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 2201.
43. Kanaji S, Kuether EL, Fahs SA, Schroeder JA, Ware J, Montgomery RR, Shi Q. Correction of Murine Bernard Soulier Syndrome by Lentivirus-Mediated Gene Therapy. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 552.
44. Du LM, Franck HWG, Merricks EP, Nurden P, Jensen ES, Haberichter SL, Hawkins TB, Jacobi PM, Fang J, Nichols TC, Koukouritaki SB, Shi Q, Montgomery RR, Cornetta K, Nurden AT, Wilcox DA. De Novo Synthesis & Storage of Human Factor VIII In Platelets Reduces Bleeding In Canine Hemophilia A. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 2198.
45. Du LM, Franck HW, Merricks EP, Nurden P, Jensen ES, Haberichter SL, Hawkins TB, Jacobi PM, Fang F, Nurden AT, Shi Q, Nichols TC, Montgomery RR, Cornetta K, and Wilcox DA. Gene Therapy Targeting Synthesis of Coagulation Factor VIII in Platelets Reduces Bleeding in Canine Hemophilia A. The American Society of Bone Marrow Transplantation Annual Meeting. Hawaii, Feb. 2011.
46. Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Amelioration of Murine VWD by platelet-

specific expression of VWF. J Thromb Haemost. July 2011;9(s2 suppl):909.

47. Chen Y, Kuether EL, Schroeder JA, Montgomery RR, Scott DW, Shi Q. Targeting FVIII Expression to Platelets Induces Immune Tolerance in Hemophilia A Mice with or without Pre-Existing Anti-FVIII Immunity, Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 4170.
48. Shi Q, Kuether E L, Fahs SA, Schroeder JA, Montgomery RR. Targeting FVIII Expression to Human Platelets Corrects the Hemophilic Phenotype in An Immunocompromised Hemophilia A Mouse Model Transplanted with Genetically Manipulated Human Cord Blood Stem Cells. Blood (ASH Annual Meeting Abstracts) 2011 118: 20.
49. Shi, Q. Lentivirus transduction of megakaryocytes: immune protection and human cell studies. 11th NHF New Technologies and Gene Therapy Workshop. The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. March 2-3, 2012.
50. Shi Q. Kuether EL, Schroeder JA, Fahs SA, Montgomery RR. Platelet Gene Therapy Corrects the Hemophilic Phenotype in Immunocompromised Hemophilia A Mice Transplanted with Genetically Manipulated Human Cord Blood Stem Cells. The 58th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Liverpool, United Kingdom. June 27-30, 2012.
51. Shi Q, Kuether EL, Schroeder JA, Perry CL, Fahs SA, Montgomery RR. VWF Exerts A Protective Effect on FVIII from Inhibitor Inactivation Both In Vitro and In Vivo. The 58th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Liverpool, United Kingdom. June 27-30, 2012.
52. Chen Y, Kuether EL, Schroeder JA, Zhang G, Montgomery RR, and Shi Q. Lentivirus-mediated Platelet Gene Therapy Corrects Bleeding Diathesis and Induces Immune Tolerance in Murine Hemophilia B Mice. Ab# 1101. The 54th ASH Annual Meeting, Atlanta, GA. December 8 – 12, 2012.
53. Kanaji S, Fahs SA, Ware J, Montgomery RR, and Shi Q. Bleeding phenotype of murine Bernard Soulier Syndrome is potentially corrected by non-myeloablative hematopoietic stem cell transplantation. Ab# 3340. The 54th ASH Annual Meeting, Atlanta, GA. December 8 – 12, 2012.
54. Kanaji S, Fahs SA, Ware J, Montgomery RR, and Shi Q. Non-myeloablative conditioning with busulfan prior to hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard Soulier Syndrome. The XXIV ISTH Congress and 59th Annual SSC Meeting. Amsterdam, Netherland, June 29 – July 4, 2013.
55. Chen Y, Kuether EL, Schroeder JA, Montgomery RR, and Shi Q. Platelet-specific expression of FIX induced by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces immune tolerance in hemophilia B mice. The XXIV ISTH Congress and 59th Annual SSC Meeting. Amsterdam, Netherland, June 29 – July 4, 2013.
56. Fahs AS, Hille M, Jozwiak M, Shi Q, Weiler H, and Montgomery RR. Factor VIII – Where is it synthesized? The XXIV ISTH Congress and 59th Annual SSC Meeting. Amsterdam, Netherland, June 29 – July 4, 2013.
57. Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Shi Q, Cornetta K, Wilcox DA. Genetic targeting of human coagulation factor VIII into platelet ?-granules resulted in long-term improvement of hemostatic function in canine hemophilia A. The XXIV ISTH Congress and 59th Annual SSC Meeting. Amsterdam, Netherland, June 29 – July 4, 2013.
58. Shi Q, Schroeder JA, Wilcox DA, Montgomery RR, and Chen Y. In vivo selection of genetically manipulated hematopoietic stem cells for platelet gene therapy of hemophilia A. Submitted to the 55th ASH Annual Meeting, New Orleans, LA. December 7-10, 2013. Accepted for Poster Presentation
59. Baumgartner KC, Shi Q, and Montgomery RR. Native whole blood thrombin generation assay evaluates therapeutic efficacy of plasma and platelet-derived FVIII. Submitted to the 55th ASH Annual Meeting, New Orleans, LA. December 7-10, 2013. Accepted for Poster Presentation
60. Shi Q. Preformed complex of VWF and FVIII provides better protection of FVIII inhibitors. International Hemophilia Meeting, Barcelona, Spain, 21 September, 2013. Invited for a lecture.
61. Shi Q. Platelet-targeted Gene Therapy of Hemophilia A and B. International Conference on Hematology & Bleeding Disorders. Raleigh, USA. September 23-25, 2013. Invited for a lecture.
62. Shi Q. FVIII inhibitors, VWF makes a different in vitro and in vivo. The Xth International hemophilia Forum. Dubai, UAE. October 24-27, 2013. Invited for a lecture.
63. Schroeder JA, Chen Y, Fang J, Wilcox DA, and Shi Q. In vivo selection of genetically manipulated platelets corrects murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection for transduction. The 60th Annual SSC Meeting. Milwaukee, USA. June 23 – 26, 2014. The Best Abstract Award. Top rated abstract in the 2014 SSC Sub Committee entitled Factor VIII and IX. Accepted for both Oral and poster presentation.
64. Baumgartner CK, Mattson JG, Shi Q, and Montgomery RR. Tracking progression of LPS induced

disseminated intravascular coagulopathy using a native whole blood thrombin generation assay. The 60th Annual SSC Meeting. Milwaukee, USA. June 23 – 26, 2014.

65. Shi Q. Interaction of VWF/FVIII and FVIII with Inhibitors: In Vitro and In Vivo. The 60th Annual SSC Meeting, Milwaukee, USA. June 23 – 26, 2014. Invited for a lecture for the Educational Section.
66. Shi Q. platelet-mediated hemophilia gene therapy. The XXII ESGCT Congress with the NVGCT. The Hague, Netherlands. October 23-26, 2014. Invited for a lecture.
67. Baumgartner CK, Roberts JC, Jacobi PM, Haberichter SL, Shi Q, and Montgomery RR. A Native Whole Blood Thrombin Generation Assay Allows Discrimination of Whole Blood Samples with FVIII Levels Below 1%. The 56th ASH Annual Meeting, San Francisco, CA. December 5-9, 2014.
68. Luo X, Schroeder JA, Baumgartner CK, Chen J, Hu J, and Shi Q. Platelet-targeted Gene Transfer Induces Antigen-specific Immune Tolerance. The 56th ASH Annual Meeting, San Francisco, CA. December 5-9, 2014.
69. Chen Y, Schroeder JA, Chen J, Luo X, Baumgartner CK, Montgomery RR, Hu J, and Shi Q. The Immunogenicity of Platelet-derived FVIII in Hemophilia A Mice with or without Pre-existing Anti-FVIII Immunity. The 56th ASH Annual Meeting, San Francisco, CA. December 5-9, 2014.
70. Chen Y, Chen J, Schroeder JA, Luo X, Baumgartner CK, Montgomery RR, Hu J, and Shi Q. The Immunogenicity of Platelets containing FVIII in Hemophilia A Mice with or without Pre-existing Anti-FVIII Immunity. The XXV ISTH Congress, Toronto, Canada. June 25-30, 2015. Top 20% of Poster by Score. Accepted for Poster Presentation.
71. Shi Q. Treatment of hemophilia A with platelet-targeted gene therapy. ". The 11th meeting of the Association de Therapy Genie du Québec (ATGQ), Quebec, Canada. June 5, 2015. Invited for a talk.
72. Baumgartner CK, Mattson JG, Weiler H, Shi Q, and Montgomery RR. Targeting FVIII expression to platelets for hemophilia A gene therapy does not bare an apparent thrombosis risk. Ab#2264. The 57th ASH Annual Meeting, Orlando, FL. December 4-8, 2015. Accepted for Poster presentation.
73. Luo X, Chen J, Schroeder JA, Baumgartner CK, Hu J, and Shi Q. Platelet-targeted gene transfer induces immune tolerance through two distinct pathways. Ab#4423. The 57th ASH Annual Meeting, Orlando, FL. December 4-8, 2015. Accepted for Poster presentation.
74. Chen Y, Luo X, Chen J, Schroeder JA, Baumgartner CK, Hu J, and Shi Q. Immune Tolerance Developed in Platelet-Targeted FVIII Gene Therapy in Hemophilia Â Mice Is CD4 T Cell-Mediated. Ab#1067. The 57th ASH Annual Meeting, Orlando, FL. December 4-8, 2015. Accepted for Poster presentation.
75. Chen J, Schroeder JA, Luo X, Montgomery RR, and Shi Q. The impact of GPIb? on the efficacy of platelet-targeted FVIII gene therapy in hemophilia A with pre-existing anti-FVIII immunity. Ab#1071. The 57th ASH Annual Meeting, Orlando, FL. December 4-8, 2015. Accepted for Poster presentation.
76. Baumgartner CK, Mattson JG, Weiler H, Shi Q, and Montgomery RR. No thrombotic risk identified with over-expression of platelet-factor VIII for hemophilia A gene therapy. The 3rd Annual Submit of the Thrombosis and Hemostasis Summit of North America (THSNA), Chicago, IL. April 14-16, 2016. Accepted for oral presentation.
77. Luo X, Chen J, Schroeder JA, Baumgartner CK, Hu J, and Shi Q. Platelet-targeted gene transfer is a promising approach for immune tolerance induction. The 3rd Annual Submit of the Thrombosis and Hemostasis Summit of North America (THSNA), Chicago, IL. April 14-16, 2016. Accepted for poster presentation.
78. Shi Q, Haribhai D, Luo X, Chen J, Schroeder JA, Aster R, Williams C B. Native TGF?1 released from platelets augments the capacity of regulatory T cells to suppress anti-FVIII immune responses in hemophilia A mice. The 3rd Annual Submit of the Thrombosis and Hemostasis Summit of North America (THSNA), Chicago, IL. April 14-16, 2016. Accepted for poster presentation.
79. Baumgartner CK, Mattson JG, Shi Q, and Montgomery RR. Targeting FVIII expression to platelets for hemophilia A gene therapy does not induce platelet hyper-activation or hyper-activatability. The 62nd Annual SSC Meeting, Montpellier, France. May 25-28, 2016. Accepted for Poster Presentation.
80. Chen J, Schroeder JA, Luo X, Montgomery RR, and Shi Q. The impact of VWF on FVIII immune responses in hemophilia A mice with pre-existing anti-FVIII immunity. Submitted to the 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. Accepted for Oral Presentation.
81. Schroeder JA, Jozwiak MA, Monahan P, and Shi Q. Platelet-derived codon-optimized hyperfunctional FIX gene therapy of hemophilia B mice. Submitted to the 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. Accepted for Poster Presentation.
82. Luo X, Li J, Chen J, Schroeder JA, Hu J, and Shi Q. Platelet-targeted gene transfer prevents graft rejection and induces immune tolerance even in A primed model. Submitted to the 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016.Accepted for Poster Presentation.

83. Luo X, Schroeder JA, Baumgartner CK, Chen J, Hu J, and Shi Q. Immune tolerance induction through platelet-targeted gene transfer. The 14th Chinese Hematology Congress, Shuzhou, China. Oct 27-29, 2016. Accepted for Oral Presentation.
84. Chen J, Schroeder JA, Luo X, and Shi Q. FVIII memory immune responses, von Willebrand factor makes a difference. The XXVI International Society of Thrombosis and Haemostasis (ISTH) Congress, Berlin, Germany, July 8-13, 2017. Accepted for Poster Presentation
85. Schroeder JA, Jozwiak MA, Monahan P, and Shi Q. Platelet-targeted Hyperfunctional FIX Gene Therapy of Hemophilia B Mice. The XXVI International Society of Thrombosis and Haemostasis (ISTH) Congress, Berlin, Germany, July 8-13, 2017. Accepted for Oral Presentation.
86. Li J, Chen J, Schroeder JA, Hu J, and Shi Q. Platelet-targeted gene transfer induces immune tolerance in a primed model. Submitted to the 59th American Society of Hematology Annual Meeting, Atlanta, GA, December 9-12, 2017.
87. Chen y, Luo X, Schroeder JA, Hu J, and Shi Q. Immune tolerance developed in platelet-targeted FVIII gene therapy in hemophilia A mice is CD4+ T cell-mediated. The 16th National Experimental Hematology Conference. Fuzhou, Fujian, China. October 20-22, 2017. Accepted for Oral Presentation.
88. Gao C, Schroeder JA, Czechowicz A, and Shi Q. Safe and effective platelet-targeted gene therapy of hemophilia A enabled using non-genotoxic, immunotoxin-based conditioning. The 4th Annual Submit of the Thrombosis and Hemostasis Summit of North America (THSNA), San Diego, CA, March 8-10, 2018. Accepted for Oral Presentation.
89. Gao C, Schroeder JA, Czechowicz A, and Shi Q. Safe and effective platelet-targeted gene therapy of hemophilia A enabled using non-genotoxic, antibody-drug-conjugate conditioning. Submitted to the 21st Annual meeting of American Society of Gene and Cell Therapy. Chicago, IL, May 16-19, 2018.
90. Li J, Chen J, Schroeder JA, and Shi Q. Platelet-specific gene transfer promotes profound targeted immune tolerance even in a primed model. The 17th Midwest Platelet Conference, Oklahoma City, OK. Oct 25-26, 2018. Accepted for Poster Presentation.
91. Luo X, Chen J, Schroeder JA, Allen KP, Baumgartner CK, Malarkannan S, Williams CB, Hu J, and Shi Q. Platelet gene therapy provokes targeted peripheral tolerance. The 15th Chinese Association Society of Hematology Meeting, Chengdu, Sichuan, China. October 25-28, 2018. Accepted for Oral Presentation.
92. Li J, Chen J, Schroeder JA, Hu J, and Shi Q. Platelet-targeted gene transfer induces immune tolerance in the primed model. The 15th Chinese Association Society of Hematology Meeting, Chengdu, Sichuan, China. October 25-28, 2018. Accepted for Oral Presentation.
93. Schroeder JA, Mattson JG, Monahan PE, and Shi Q. Platelet-targeted hyperfunctional factor IX (FIX) gene therapy for hemophilia B mice with pre-existing anti-FIX immunity. The 60th American Society of Hematology Annual Meeting, San Diego, CA, December 1-4, 2018. Accepted for Oral Presentation.
94. Chen Y, Schroeder JA, Hu J, and Shi Q. In vivo enrichment of genetically manipulated platelets of murine hemophilia B gene therapy. The 60th American Society of Hematology Annual Meeting, San Diego, CA, December 1-4, 2018. Accepted for Poster Presentation.
95. Shi Q, Mattson JG, Fahs SA, and Montgomery RR. The severe spontaneous bleeding phenotype is a novel hemophilia A rat model with inversion mutation is rescued by platelet targeted FVIII expression. The 60th American Society of Hematology Annual Meeting, San Diego, CA, December 1-4, 2018. Accepted for Oral Presentation.
96. Montgomery RR, Fahs SA; Mattson JG, Weiler H, and Shi Q. A murine model of Type 2N VWD was developed by CRISPR/Cas9 gene editing and recapitulates human Type 2N VWD. The 60th American Society of Hematology Annual Meeting, San Diego, CA, December 1-4, 2018. Accepted for Oral Presentation.
97. Shi Q, Carmen CV, Chen Y, Xue F, Liang X, and Gilbert GE. Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice. The XXVII International Society of Thrombosis and Haemostasis (ISTH) Congress, Malborne, Australia, July 6-10, 2019. Accepted for Oral Presentation.
98. Chen Y, Schroeder JA, Hu J, and Shi Q. In vivo enrichment of genetically manipulated platelets of murine hemophilia B gene therapy. The XXVII International Society of Thrombosis and Haemostasis (ISTH) Congress, Malborne, Australia, July 6-10, 2019. Accepted for Oral Presentation.
99. Shi Q, Mattson JG, Fahs SA, and Montgomery RR. Platelet-targeted FVIII gene therapy effectively prevent the spontaneous bleeding phenotype in severe hemophilia A rats. The XXVII International Society of Thrombosis and Haemostasis (ISTH) Congress, Malborne, Australia, July 6-10, 2019. Accepted for Poster Presentation.
100. Gao C, Schroeder JA, Czechowicz A, and Shi Q. Using non-genotoxic, antibody-drug-conjugate

conditioning enables safe and effective platelet-specific FVIII gene therapy of hemophilia A. The XXVII International Society of Thrombosis and Haemostasis (ISTH) Congress, Malborne, Australia, July 6-10, 2019. Accepted for Poster Presentation.

101. Shi Q. Platelet-targeted gene therapy for hemophilia B mice with pre-existing anti-FIX immunity. Platelet and Thrombosis Symposium (Malborne, Australia, July 5, 2019). The XXVII International Society of Thrombosis and Haemostasis (ISTH) Congress, Malborne, Australia, July 6-10, 2019. Invited for a talk.
102. Chen Y, Schroeder JA, Hu J, and Shi Q. MGMT-mediated drug-selection to enrich genetically manipulated platelets for murine hemophilia B gene therapy. The 8th East Asia Hemophilia Forum, Tianjin, China. August 8-10. Accepted for Oral Presentation.
103. Jing W, Chen J. Cai Y, Chen Y, Schroeder JA, Cui W, and Shi Q. Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice. The 61st American Society of Hematology (ASH) Annual Meeting, Orlando, FL, December 7-10, 2019. Accepted for Oral Presentation.
104. Chen Y, Li J, Schroeder JA, Jing W, Hu J, and Shi Q. Fludarabine in combination with busulfan as pretransplant conditioning for platelet gene therapy in murine hemophilia A with inhibitors. The 61st American Society of Hematology (ASH) Annual Meeting, Orlando, FL, December 7-10, 2019. Accepted for Poster Presentation.
105. Castillo M, Yang Q, McKinney D, Shi, Q, and Sood R. Animal models demonstrate a critical role of factor VIII in Par4- and platelet-mediated pathology. The 61st American Society of Hematology (ASH) Annual Meeting, Orlando, FL, December 7-10, 2019. Accepted for Poster presentation.
106. Li J, Chen J, Schroeder JA, and Shi Q. Robust antigen-specific immune tolerance can be achieved in a primed model by platelet-targeted gene therapy via peripheral clonal deletion and Treg cell expansion. The 23rd Annual Meeting of American Society of Gene and Cell Therapy (ASGCT). May 12-15, 2020. Boston, MA. Accepted for Oral Presentation.
107. Schroeder JA, Monahan P, and Shi Q. Platelet-targeted hyperactive factor IX (FIX) gene therapy for hemophilia B mice with pre-existing anti-FIX immunity. The XXVIII International Society of Thrombosis and Haemostasis (ISTH) Congress. July 11-15, 2020. Milan, Italy. Accepted for Poster Presentation.
108. Shi Q. Utilizing platelets as a targeted for gene therapy of hemophilia A and hemophilia B". Microscopy and Microanalysis 2020. Symposium: B07.2 ? Biomedical and Pharmaceutical Research on the Development, Diagnosis, Prevention, and treatment of Diseases. Milwaukee, WI. August 2-6, 2020. Invited Speaker.
109. Jing L, Chen J, Schroeder JA, and Shi Q. Platelet-targeted gene therapy induces robust immune tolerance even in a primed model via peripheral clonal deletion of CD4 and CD8 T cells and expansion of Treg cells. The 62nd American Society of Hematology (ASH) Annual Meeting, San Diego, CA, December 5-8, 2020. Accepted for Poster Presentation.
110. Shi Q. "Platelet-specific gene therapy for hemophilia A". The Center for Blood Research, the University of British Columbia, Vancouver, Canada. Virtual Seminar Series, March 24, 2021. Invited lecture.
111. Chen Y, Li J, Schroeder JA, Jing W, Hu J, and Shi Q. Clinical translatable preconditioning for platelet gene therapy in murine hemophilia A with inhibitors. The XXVIII International Society of Thrombosis and Haemostasis (ISTH) Virtual Congress. July 17-21, 2021. Accepted for Poster Presentation. The abstract has been judged as a significant contribution to the coagulation community and highlighted in the year's Official Highlights of ISTH 2021 meeting (Oct 21-Nov 12, 2021) in the session on Gene Therapy in Hemophilia.
112. Cai Y, Jing W, Schroeder JA, and Shi Q. The role of VWF/FVIII association in anti-FVIII immune responses in hemophilia A mice. The XXIX International Society of Thrombosis and Haemostasis (ISTH) Virtual Congress. July 17-21, 2021. Accepted for Oral Presentation. The abstract has been judged as a significant contribution to the coagulation community and highlighted in the year's Official Highlights of ISTH 2021 meeting (Oct 21-Nov 12, 2021) in the session on Hemophilia (Non-gene therapy).
113. Yu H, Schroeder JA, Mattson JG, and Shi Q. The impact of platelet ?IIb?3 on the hemostatic efficacy of platelet-derived FVIII gene therapy. The XXIX International Society of Thrombosis and Haemostasis (ISTH) Virtual Congress. July 17-21, 2021. Accepted for Poster Presentation.
114. Wilcox DA, Armant M, Du L, Johnson B, Bushman F, Jobe S, Shi Q, Malec L, and Hari P. Platelet-targeted FVIII "PleightletTM" LV-HSC for severe hemophilia A pre-clinical research supporting a clinical protocol for a first-in human trial. The 2021 NHF's Annual Bleeding Disorders Virtual Conference,

August 25-28, 2021.

115. Jing W, Baumgartner C, Xue F, Schroeder JA, and Shi Q. Pre-existing anti-FVIII immunity alters therapeutic platelet-targeted FVIII engraftment in the system preconditioned with busulfan alone through cytotoxic CD8 T cells. The 62nd American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, December 11-14, 2021. Accepted for Oral Presentation.
116. Shi Q. Platelet-specific gene therapy for hemophilia. Advancing gene therapy 2022. Boston, MA. March 28-30, 2022. Invited speaker.
117. Jing W, Xue F, Schroeder JA, and Shi Q. Therapeutic platelet-targeted FVIII engraftment was altered in a FVIII-primed system preconditioned with busulfan alone through cytotoxic CD8 T cells. The American Society Gene and Cell Therapy (ASGCT) 25th Annual Meeting. Washington, DC, May 16-19, 2022. Accepted for Poster Presentation.
118. Jing W, Chen J, Cai Y, Schroeder JA, Dent AL, and Shi Q. Follicular regulatory T cells promote anti-FVIII inhibitor development in hemophilia A mice. The XXX International Society of Thrombosis and Haemostasis (ISTH) Congress. London, England, UK, July 9-13, 2022. Accepted for Oral Presentation.
119. Chen YY, Chen YW, Luo L, Zhen Q, Yirza SK, Shi Q, and Hu J. Association of platelet desialylation and circulating follicular helper T cells in patients with thrombocytopenia. The XXX International Society of Thrombosis and Haemostasis (ISTH) Congress. London, England, UK, July 9-13, 2022. Accepted for Poster Presentation.
120. Yu H, Schroeder JA, Mattson JG, and Shi Q. Platelet ?IIb?3 receptor antagonist impedes the hemostatic efficacy of platelet-specific FVIII gene therapy in hemophilia A mice. The 63rd American Society of Hematology (ASH) Annual Meeting. Orleans, LO. Dec 10-13, 2022. Accepted for poster presentation.
121. Cai Y, Schroeder JA, Jing W, Gurski C, Williams CB, Dittel BN, Shi Q. Induction of immune tolerance in experimental autoimmune encephalomyelitis utilizing platelet-targeted gene therapy. The 19th Biennial Midwest Platelet Conference. Ann Arbor, MI, Oct 6-8, 2022. Accepted for Oral Presentation
122. Zhang z, Yu H, Mattson J, Lund H, Dai W, Rodrigues ASM, Zhang H, Montgomery RR, Shi Q, Malec LM, Zheng z. FVIII deficiency leads to lower atherogenic ApoB-lipoprotein and higher fibrinolysis. Hemostasis & Thrombosis Research Society (HTRS) 2023 Scientific Symposium, Orlando, FL. Mar 10-12, 2023. Accepted for Oral Presentation.
123. Shi Q. Platelet gene therapy for autoimmune disease multiple sclerosis. The First Look Forum 2023, Organized by UW-Milwaukee, MCW, and Marquette University. Rockwell Automation, Inc., Milwaukee, WI. April 20th, 2023. Invited lecture.
124. Chen Y, Luo L, Zheng Q, Chen Z, Shi Q. Association of chemokine CXCL13 and follicular helper T cells in hemophilia A patient and murine model with inhibitors. Montrèal, Quebec, Canada, June 24-28, 2023. Accepted for Oral Presentation.
125. Chen Y, Xue F, Schroeder JA, and Shi Q. Immune modulatory function of desialylated platelets containing FVIII in FVIII immune responses in hemophilia A mice. Abstract submitted to The XXXI International Society of Thrombosis and Haemostasis (ISTH) Congress. Montrèal, Quebec, Canada, June 24-28, 2023.
126. Schroeder JA, Yu H, Rapten J, Fahs SA, Montgomery RR, and Shi Q. VWF type 2N variant markedly enhances FVIII levels when both proteins are expressed in platelets. Abstract submitted to The XXXI International Society of Thrombosis and Haemostasis (ISTH) Congress. Montrèal, Quebec, Canada, June 24-28, 2023.
127. Jing W, Schroeder JA, Chen J, Cai Y, Kumar S, Dent AL, and Shi Q. The Tfh/Tfr pathway is pivotal in FVIII inhibitor development in mice. Submitted to the 65th American Society of Hematology (ASH) Annual Meeting. San Diego, CA. Dec 9-12, 2023.